Predictors of unsuppressed viral load among adults on follow up of antiretroviral therapy at selected public and private health facilities of Adama town: unmached case-control study.
Adherence
Case -control
Oromia
Unsuppressed viral load
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
19 09 2022
19 09 2022
Historique:
received:
26
02
2022
accepted:
12
09
2022
entrez:
19
9
2022
pubmed:
20
9
2022
medline:
23
9
2022
Statut:
epublish
Résumé
Despite the scale up of antiretroviral therapy (ART), unsuppressed viral load among population taking ART in private and public health facilities is still a public health concern increasing the risk of treatment failure. Studies comprehensively assessing significant predictors of non-suppressed viral load among patients on follow up of AR in public and private health facilities are limited. The objective of the study was to identify predictors of unsuppressed viral load among adult patients taking antiretroviral therapy at selected public and private health facilities of Adama town, East shewa zone, Ethiopia. An unmatched case-control study was conducted from April 15 /2021 to May 20/2021. A total sample size of 347 patients consisting 116 cases and 231 controls was selected from electronic database among patients who started ART from September 2015 to August 2020. Data were collected using checklist from patient medical records and analyzed by SPSS. The association of dependent and independent variables was determined using multivariate analysis with 95% confidence interval and P - value in logistic regression model to identify independent predictors. From the total 347 participants, 140 (40.3%) of them were males and 207 (59.7%) were females. In multivariate logistic regression, CD4 count < 100 [(AOR:1.22, 95% CI: 1.4-7.3)], CD4 100-200[(AOR: 2.58 95% CI: 1.06-8.28)], Fair Adherence [(AOR: 2.44, 95% CI: 1.67-4.82)], poor adherence [(AOR: 1.11, 95% CI: 1.7-6.73)], History of Cotrimoxazole Therapy (CPT) use and not used [(AOR: 2.60, 95% CI: 1.23-5.48)] and History of drug substitution [(AOR:. 361, 95% CI: .145-.897)] were independent predictors of unsuppressed viral load with the p-value less than 0.05. In this study, Baseline CD4, adherence, History of CPT used and history of drug substitution was predictors of unsuppressed viral load. Monitoring immunological response through scheduled CD4 tests is essential to maintain immunity of the patients preventing diseases progression. Intensive adherence support and counseling should conclusively be provided through effective implementation of ART programs by providers would enhance viral suppression ensuring the quality of care and treatment.
Sections du résumé
BACKGROUND
Despite the scale up of antiretroviral therapy (ART), unsuppressed viral load among population taking ART in private and public health facilities is still a public health concern increasing the risk of treatment failure. Studies comprehensively assessing significant predictors of non-suppressed viral load among patients on follow up of AR in public and private health facilities are limited. The objective of the study was to identify predictors of unsuppressed viral load among adult patients taking antiretroviral therapy at selected public and private health facilities of Adama town, East shewa zone, Ethiopia.
METHODS
An unmatched case-control study was conducted from April 15 /2021 to May 20/2021. A total sample size of 347 patients consisting 116 cases and 231 controls was selected from electronic database among patients who started ART from September 2015 to August 2020. Data were collected using checklist from patient medical records and analyzed by SPSS. The association of dependent and independent variables was determined using multivariate analysis with 95% confidence interval and P - value in logistic regression model to identify independent predictors.
RESULT
From the total 347 participants, 140 (40.3%) of them were males and 207 (59.7%) were females. In multivariate logistic regression, CD4 count < 100 [(AOR:1.22, 95% CI: 1.4-7.3)], CD4 100-200[(AOR: 2.58 95% CI: 1.06-8.28)], Fair Adherence [(AOR: 2.44, 95% CI: 1.67-4.82)], poor adherence [(AOR: 1.11, 95% CI: 1.7-6.73)], History of Cotrimoxazole Therapy (CPT) use and not used [(AOR: 2.60, 95% CI: 1.23-5.48)] and History of drug substitution [(AOR:. 361, 95% CI: .145-.897)] were independent predictors of unsuppressed viral load with the p-value less than 0.05.
CONCLUSION AND COMMENDATION
In this study, Baseline CD4, adherence, History of CPT used and history of drug substitution was predictors of unsuppressed viral load. Monitoring immunological response through scheduled CD4 tests is essential to maintain immunity of the patients preventing diseases progression. Intensive adherence support and counseling should conclusively be provided through effective implementation of ART programs by providers would enhance viral suppression ensuring the quality of care and treatment.
Identifiants
pubmed: 36123609
doi: 10.1186/s12889-022-14169-7
pii: 10.1186/s12889-022-14169-7
pmc: PMC9484167
doi:
Substances chimiques
Trimethoprim, Sulfamethoxazole Drug Combination
8064-90-2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1770Informations de copyright
© 2022. The Author(s).
Références
Epidemiol Infect. 2021 Mar 22;149:e88
pubmed: 33745490
Open AIDS J. 2012;6:16-25
pubmed: 22435082
J Acquir Immune Defic Syndr. 2012 Aug 1;60(4):428-37
pubmed: 22433846
Lancet Infect Dis. 2010 Mar;10(3):155-66
pubmed: 20185094
BMC Infect Dis. 2019 Apr 3;19(1):305
pubmed: 30943903
BMC Pharmacol Toxicol. 2019 Nov 1;20(1):63
pubmed: 31675986
PLoS One. 2018 Nov 9;13(11):e0200242
pubmed: 30412576
J Virus Erad. 2016 Apr 01;2(2):94-101
pubmed: 27482442
Int J Mycobacteriol. 2019 Apr-Jun;8(2):113-117
pubmed: 31210151
BMC Infect Dis. 2021 Aug 2;21(1):731
pubmed: 34340689
HIV AIDS (Auckl). 2020 Sep 07;12:393-402
pubmed: 33061655
Ital J Pediatr. 2021 Apr 6;47(1):84
pubmed: 33823890
BMC Infect Dis. 2020 Jan 2;20(1):4
pubmed: 31898535
Int J STD AIDS. 2018 May;29(6):603-610
pubmed: 29334886
HIV AIDS (Auckl). 2021 May 14;13:513-526
pubmed: 34017201
BMC Infect Dis. 2020 Jul 1;20(1):460
pubmed: 32611405
J Immunol Res. 2021 Apr 09;2021:2498025
pubmed: 33928167
HIV AIDS (Auckl). 2020 Dec 14;12:931-939
pubmed: 33363411